New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 18, 2014
09:00 EDTACRXAcelRx attractive ahead of Zalviso PDUFA, says Roth Capital
Roth Capital believes that AcelRx's Zalviso has the potential to replace IV PCA across many U.S. hospitals for treating patients with moderate-to-severe pain. The firm thinks the drug is likely to be approved next week and views the stock's recent weakness as a buying opportunity.
News For ACRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
17:05 EDTACRXAcelRx enters into separation agreement with CEO Richard King
Subscribe for More Information
07:30 EDTACRXGuggenheim to hold a conference
Subscribe for More Information
December 10, 2014
08:04 EDTACRXRoth Capital to hold an event
Corporate Access Event 2014 is being held in Park City, Utah on December 10-12.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use